*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter - as a primary or secondary diagnosis code | ||
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | ||
| Readmission Rate (%) | ||
| Unplanned Readmission Rate (%) | 15.19 | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 641: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 640: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 392: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 310,318 | ||||
| Total Hospitalizations with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 306 | ||||
| DRG Share of Total Hospitalizations | 0.94 | ||||
| % of Total ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter in DRG | 9.22 | ||||
| Avg LOS at DRG | 3.19 | ||||
| Avg LOS with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 2.93 | ||||
| Readmission Rate at DRG | 20.19 | ||||
| Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 17.47 | ||||
| Unplanned Readmission Rate at DRG | 13.62 | ||||
| Unplanned Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 12.33 | ||||
| Total Medicare payments at DRG | $1,415,392,709 | ||||
| Total Medicare payments with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $1,325,369 | ||||
| Total Medicare payment per Day at DRG | $1,431 | ||||
| Total Medicare payment per Day with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $1,479 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,561 | ||||
| Total Medicare payment per Hospitalization with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $4,331 | ||||
| Total Medicare Charges at DRG | $7,113,640,596 | ||||
| Total Medicare Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $7,253,887 | ||||
| Avg Charges at DRG | $22,924 | ||||
| Avg Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $23,706 | ||||
| Mortality Rate at DRG | 0.63 | ||||
| Mortality Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 19.76 | ||||
| SNF Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 11.44 | ||||
| Home Discharge Rate at DRG | 50.47 | ||||
| Home Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 66.01 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 378: G.I. HEMORRHAGE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 682: RENAL FAILURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 394: OTHER DIGESTIVE SYSTEM DIAGNOSES WITH COMPLICATION OR COMORBIDITY (CC) | DRG 291: HEART FAILURE AND SHOCK WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 439: DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 408,103 | ||||
| Total Hospitalizations with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 97 | ||||
| DRG Share of Total Hospitalizations | 1.24 | ||||
| % of Total ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter in DRG | 2.92 | ||||
| Avg LOS at DRG | 3.52 | ||||
| Avg LOS with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 4.12 | ||||
| Readmission Rate at DRG | 17.83 | ||||
| Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 21.05 | ||||
| Unplanned Readmission Rate at DRG | 13.81 | ||||
| Unplanned Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 20.0 | ||||
| Total Medicare payments at DRG | $2,416,862,532 | ||||
| Total Medicare payments with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $564,808 | ||||
| Total Medicare payment per Day at DRG | $1,682 | ||||
| Total Medicare payment per Day with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $1,412 | ||||
| Total Medicare payment per Hospitalization at DRG | $5,922 | ||||
| Total Medicare payment per Hospitalization with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $5,823 | ||||
| Total Medicare Charges at DRG | $13,267,744,847 | ||||
| Total Medicare Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $3,707,408 | ||||
| Avg Charges at DRG | $32,511 | ||||
| Avg Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $38,221 | ||||
| Mortality Rate at DRG | 0.72 | ||||
| Mortality Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 14.1 | ||||
| SNF Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 62.97 | ||||
| Home Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 61.86 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 690: KIDNEY AND URINARY TRACT INFECTIONS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 391: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 440: DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 872: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 474,314 | ||||
| Total Hospitalizations with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 51 | ||||
| DRG Share of Total Hospitalizations | 1.44 | ||||
| % of Total ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter in DRG | 1.54 | ||||
| Avg LOS at DRG | 3.53 | ||||
| Avg LOS with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 4.51 | ||||
| Readmission Rate at DRG | 18.03 | ||||
| Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| Unplanned Readmission Rate at DRG | 12.55 | ||||
| Unplanned Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| Total Medicare payments at DRG | $2,312,733,090 | ||||
| Total Medicare payments with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $284,755 | ||||
| Total Medicare payment per Day at DRG | $1,380 | ||||
| Total Medicare payment per Day with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $1,238 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,876 | ||||
| Total Medicare payment per Hospitalization with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $5,583 | ||||
| Total Medicare Charges at DRG | $11,559,952,314 | ||||
| Total Medicare Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $1,605,248 | ||||
| Avg Charges at DRG | $24,372 | ||||
| Avg Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $31,475 | ||||
| Mortality Rate at DRG | 0.22 | ||||
| Mortality Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 25.96 | ||||
| SNF Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 43.58 | ||||
| Home Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 52.94 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 193: SIMPLE PNEUMONIA AND PLEURISY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 377: G.I. HEMORRHAGE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 309: CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 948: SIGNS AND SYMPTOMS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 190: CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 443,386 | ||||
| Total Hospitalizations with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 32 | ||||
| DRG Share of Total Hospitalizations | 1.35 | ||||
| % of Total ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter in DRG | 0.96 | ||||
| Avg LOS at DRG | 5.27 | ||||
| Avg LOS with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | 7.16 | ||||
| Readmission Rate at DRG | 21.6 | ||||
| Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| Unplanned Readmission Rate at DRG | 15.91 | ||||
| Unplanned Readmission Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| Total Medicare payments at DRG | $3,812,834,208 | ||||
| Total Medicare payments with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $306,290 | ||||
| Total Medicare payment per Day at DRG | $1,632 | ||||
| Total Medicare payment per Day with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $1,338 | ||||
| Total Medicare payment per Hospitalization at DRG | $8,599 | ||||
| Total Medicare payment per Hospitalization with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $9,572 | ||||
| Total Medicare Charges at DRG | $18,110,468,211 | ||||
| Total Medicare Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $1,950,555 | ||||
| Avg Charges at DRG | $40,846 | ||||
| Avg Charges with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | $60,955 | ||||
| Mortality Rate at DRG | 3.59 | ||||
| Mortality Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 22.57 | ||||
| SNF Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 40.95 | ||||
| Home Discharge Rate with ICD T471X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter | NA |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| MAYO CLINIC HOSPITAL - SAINT MARYS CAMPUS | 1216 2ND ST SW | ROCHESTER | MN | 55902 | 23 |
| BETH ISRAEL DEACONESS MEDICAL CENTER | 330 BROOKLINE AVE | BOSTON | MA | 02215 | 20 |
| UNIVERSITY OF IOWA HOSPITAL & CLINICS | 200 HAWKINS DR | IOWA CITY | IA | 52242 | 15 |